Genetic association of lipid-lowering drugs with aortic aneurysms: a Mendelian randomization study
- PMID: 38302118
- DOI: 10.1093/eurjpc/zwae044
Genetic association of lipid-lowering drugs with aortic aneurysms: a Mendelian randomization study
Abstract
Aims: The lack of effective pharmacotherapies for aortic aneurysms (AA) is a persistent clinical challenge. Lipid metabolism plays an essential role in AA. However, the impact of lipid-lowering drugs on AA remains controversial. The study aimed to investigate the genetic association between lipid-lowering drugs and AA.
Methods and results: Our research used publicly available data on genome-wide association studies (GWASs) and expression quantitative trait loci (eQTL) studies. Genetic instruments, specifically eQTLs related to drug-target genes and SNPs (single nucleotide polymorphisms) located near or within the drug-target loci associated with low-density lipoprotein cholesterol (LDL-C), have been served as proxies for lipid-lowering medications. Drug-Target Mendelian Randomization (MR) study is used to determine the causal association between lipid-lowering drugs and different types of AA. The MR analysis revealed that higher expression of HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase) was associated with increased risk of AA (OR = 1.58, 95% CI = 1.20-2.09, P = 1.20 × 10-03) and larger lumen size (aortic maximum area: OR = 1.28, 95% CI = 1.13-1.46, P = 1.48 × 10-04; aortic minimum area: OR = 1.26, 95% CI = 1.21-1.42, P = 1.78 × 10-04). PCSK9 (proprotein convertase subtilisin/kexin type 9) and CETP (cholesteryl ester transfer protein) show a suggestive relationship with AA (PCSK9: OR = 1.34, 95% CI = 1.10-1.63, P = 3.07 × 10-03; CETP: OR = 1.38, 95% CI = 1.06-1.80, P = 1.47 × 10-02). No evidence to support genetically mediated NPC1L1 (Niemann-Pick C1-Like 1) and LDLR (low-density lipoprotein cholesterol receptor) are associated with AA.
Conclusion: This study provides causal evidence for the genetic association between lipid-lowering drugs and AA. Higher gene expression of HMGCR, PCSK9, and CETP increases AA risk. Furthermore, HMGCR inhibitors may link with smaller aortic lumen size.
Keywords: Aortic aneurysms; Causal relationship; Genetic instruments; Lipid-lowering drugs; Mendelian randomization.
Plain language summary
This Mendelian randomization study used publicly available data involving over 1 million individuals to demonstrate the causal relationship between five target genes of LDL-C-lowering medicines and the risk of aortic aneurysms, and implied one lipid-lowering drug may link with the lumen size of aortic aneurysms.
Key findings: High expression of HMGCR, PCSK9, and CETP was positively correlated with the risk of aortic aneurysms, highlighting that the corresponding lipid-lowering drugs may be preferred for preventing arterial aneurysms in high-risk individuals with dyslipidemia. We found that genetically predicted HMGCR inhibitors were positively associated with smaller aortic lumen size, which is the first time to support the causal association of gene HMGCR on the lumen size of aortic aneurysms.
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.
Conflict of interest statement
Conflict of interest: none declared.
Similar articles
-
Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study.Eur Heart J Cardiovasc Pharmacother. 2025 Mar 13;11(2):136-142. doi: 10.1093/ehjcvp/pvae092. Eur Heart J Cardiovasc Pharmacother. 2025. PMID: 39611306 Free PMC article.
-
Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.PLoS Genet. 2021 Apr 22;17(4):e1009525. doi: 10.1371/journal.pgen.1009525. eCollection 2021 Apr. PLoS Genet. 2021. PMID: 33886544 Free PMC article.
-
Causal Association Between Cholesterol-Lowering Drugs and Diabetic Microvascular Complications: A Drug-Target Mendelian Randomization Study.J Diabetes Res. 2025 Feb 28;2025:3661739. doi: 10.1155/jdr/3661739. eCollection 2025. J Diabetes Res. 2025. PMID: 40225015 Free PMC article.
-
Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis.JAMA Cardiol. 2018 Jan 1;3(1):26-33. doi: 10.1001/jamacardio.2017.4293. JAMA Cardiol. 2018. PMID: 29188294 Free PMC article. Review.
-
New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia.Curr Med Chem. 2012;19(28):4861-8. doi: 10.2174/092986712803341485. Curr Med Chem. 2012. PMID: 22963620 Review.
Cited by
-
Genetic association analysis between LDL-c lowering drugs and portal hypertension using Mendelian randomization analysis.Sci Rep. 2025 Jul 1;15(1):22238. doi: 10.1038/s41598-025-08153-5. Sci Rep. 2025. PMID: 40596422 Free PMC article.
-
Multi-Omic Insight Into the Molecular Networks of Mitochondrial Dysfunction in the Pathogenesis of Primary Open-Angle Glaucoma.Transl Vis Sci Technol. 2025 Jun 2;14(6):37. doi: 10.1167/tvst.14.6.37. Transl Vis Sci Technol. 2025. PMID: 40586668 Free PMC article.
-
Integrative bioinformatics frameworks for abdominal aortic aneurysm using GWAS meta-analysis, biological network construction, and structural modeling.Sci Rep. 2025 Jul 1;15(1):22331. doi: 10.1038/s41598-025-07989-1. Sci Rep. 2025. PMID: 40595262 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous